Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LR-ESHAP for Relapsed/Refractory DLBCL
NCT02340936Phase 2Completed
- Sponsor
- GELTAMO
- Start
- Jan 2011
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by GELTAMO. Started Jan 2011; status: completed.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02340936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02340936.